

Amendments to the Specification:

Please delete the paragraph beginning at page 7, line 4, which starts with “FIG. 12 is.”

Please replace the paragraph beginning at page 7, line 5 with the following amended paragraph:

--FIG. [[13]] 12 is a series of photomicrographs depicting NEM selectively binding to prostate cancer cells.--

Please replace the paragraph beginning at page 7, line 7 with the following amended paragraph:

--FIG. [[14]] 13 is series of photomicrographs of immunohisto-chemical detection of NEM in prostate cancer tissue sections, and detection of NEM in secondary sites of prostate cancer.--

Please replace the paragraph beginning at page 7, line 9 with the following amended paragraph:

--FIG. [[15]] 14 is a series of photomicrographs of the expression of NEM in BPH and prostate cancer tissue sections.--

Please delete the paragraph beginning at page 7, line 11, which starts with “FIG. 16 is.”

Please delete the paragraph beginning at page 7, line 13, which starts with “FIG. 17 is.”

Please delete the paragraph beginning at page 7, line 15, which starts with “FIG. 18 is.”

Please delete the paragraph beginning at page 7, line 16, which starts with “FIG. 19 is.”

Please replace the paragraph beginning at page 15, line 22 with the following amended paragraph:

--Antibodies directed against NEM block the growth and the metastatic potential of prostate cancer cells grown in culture. As shown in Fig. [[13]] 12, NEM selectively binds to NEM receptors on prostate cancer cells. The binding of the antibodies to NEM prevents NEM's interaction with its

Appl. No. 09/251,133
Amdt. Dated November 11, 2003
Reply to Notice of Allowability

specific receptors, thereby inhibiting its growth promoting and metastatic properties. The pathway is illustrated in Fig. [[12]] 9--